Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Bluejay Diagnostics ( (BJDX) ) is now available.
On December 29, 2025, Bluejay Diagnostics announced it had completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6), a key biomarker for inflammatory and critical-care applications, with both antibody types meeting internal performance criteria for use in Symphony cartridge manufacturing. Internal testing showed acceptable binding, specificity and signal performance for the monoclonal detection antibodies, and the company now estimates its IL-6 antibody inventory could support production of more than nine million Symphony cartridges while also having the capability to produce additional antibodies, marking a significant operational milestone for scaling the Symphony platform even as the system remains under development and subject to further validation and regulatory review.
Spark’s Take on BJDX Stock
According to Spark, TipRanks’ AI Analyst, BJDX is a Underperform.
Bluejay Diagnostics’ stock is heavily impacted by its poor financial performance, with no revenue and continuous losses. The technical indicators suggest a bearish trend, and valuation is challenging due to the negative P/E ratio. Improvements in equity are noted but overshadowed by the lack of profitability and revenue generation.
To see Spark’s full report on BJDX stock, click here.
More about Bluejay Diagnostics
Bluejay Diagnostics is a medical diagnostics company developing the Symphony System, a cost-effective, rapid, near-patient testing platform aimed at sepsis triage and monitoring disease progression. Its first product candidate is an IL-6 test for sepsis designed to deliver accurate results in about 20 minutes from sample to result, but the Symphony System has not yet received U.S. Food and Drug Administration clearance and cannot currently be marketed as a diagnostic product in the United States.
Average Trading Volume: 2,590,238
Technical Sentiment Signal: Sell
Current Market Cap: $1.27M
Learn more about BJDX stock on TipRanks’ Stock Analysis page.